Inflammatory mass lesions associated with intrathecal drug infusion catheters: Report and observations on 41 patients

Robert J. Coffey, Kim Burchiel

Research output: Contribution to journalArticle

164 Citations (Scopus)

Abstract

OBJECTIVE: Several reports have described inflammatory mass lesions at the tip of intraspinal drug administration catheters. We evaluated the number of patients reported with this condition and whether data support hypotheses that have been put forth regarding the cause of these lesions. METHODS: Information that was reported in the medical literature, and by Medtronic, Inc., to the United States Food and Drug Administration as of November 30, 2000, was reviewed. RESULTS: Forty-one cases were identified, including 16 from the literature and 25 that were not published previously in the literature. Because of voluntary reporting and other methodological limitations, the actual number of cases must be higher than reported. All of the patients had chronic pain. The mean duration of therapy was 24.5 months. Most masses were located in the thoracic region, Intrathecal drugs included morphine or hydromorphone, either alone or mixed with other drugs, in 39 of 41 cases. No masses were reported in patients who received baclofen as the only intrathecal medication. Thirty patients underwent surgery to relieve spinal cord or cauda equina compression. Eleven patients were nonambulatory at last follow-up, and one died of a pulmonary embolus. Surgical specimens revealed noninfectious chronic inflammation, granuloma formation, and fibrosis or necrosis. DISCUSSION: The most plausible hypothesis with regard to the cause of intrathecal catheter tip mass lesions implicates the administration of relatively high-concentration or high-dose opiate drugs or the use of drugs and admixtures that are not labeled for intrathecal use. CONCLUSION: Patients who require high-dose intraspinal opioid therapy and those who receive drugs or admixtures that are not approved for intrathecal use should be monitored closely for signs of an extra-axial mass or catheter malfunction. Prompt diagnosis and treatment may preserve neurological function.

Original languageEnglish (US)
Pages (from-to)78-86
Number of pages9
JournalNeurosurgery
Volume50
Issue number1
DOIs
StatePublished - Jan 2002

Fingerprint

Catheters
Pharmaceutical Preparations
Opiate Alkaloids
Hydromorphone
Cauda Equina
Baclofen
United States Food and Drug Administration
Granuloma
Embolism
Chronic Pain
Morphine
Opioid Analgesics
Spinal Cord
Fibrosis
Necrosis
Thorax
Therapeutics
Inflammation
Lung

Keywords

  • Complications
  • Granuloma
  • Inflammatory mass
  • Intraspinal drug therapy
  • Intrathecal catheter
  • Morphine pump

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

Inflammatory mass lesions associated with intrathecal drug infusion catheters : Report and observations on 41 patients. / Coffey, Robert J.; Burchiel, Kim.

In: Neurosurgery, Vol. 50, No. 1, 01.2002, p. 78-86.

Research output: Contribution to journalArticle

@article{981061bac6314d0ab668e4f4d51ce7d1,
title = "Inflammatory mass lesions associated with intrathecal drug infusion catheters: Report and observations on 41 patients",
abstract = "OBJECTIVE: Several reports have described inflammatory mass lesions at the tip of intraspinal drug administration catheters. We evaluated the number of patients reported with this condition and whether data support hypotheses that have been put forth regarding the cause of these lesions. METHODS: Information that was reported in the medical literature, and by Medtronic, Inc., to the United States Food and Drug Administration as of November 30, 2000, was reviewed. RESULTS: Forty-one cases were identified, including 16 from the literature and 25 that were not published previously in the literature. Because of voluntary reporting and other methodological limitations, the actual number of cases must be higher than reported. All of the patients had chronic pain. The mean duration of therapy was 24.5 months. Most masses were located in the thoracic region, Intrathecal drugs included morphine or hydromorphone, either alone or mixed with other drugs, in 39 of 41 cases. No masses were reported in patients who received baclofen as the only intrathecal medication. Thirty patients underwent surgery to relieve spinal cord or cauda equina compression. Eleven patients were nonambulatory at last follow-up, and one died of a pulmonary embolus. Surgical specimens revealed noninfectious chronic inflammation, granuloma formation, and fibrosis or necrosis. DISCUSSION: The most plausible hypothesis with regard to the cause of intrathecal catheter tip mass lesions implicates the administration of relatively high-concentration or high-dose opiate drugs or the use of drugs and admixtures that are not labeled for intrathecal use. CONCLUSION: Patients who require high-dose intraspinal opioid therapy and those who receive drugs or admixtures that are not approved for intrathecal use should be monitored closely for signs of an extra-axial mass or catheter malfunction. Prompt diagnosis and treatment may preserve neurological function.",
keywords = "Complications, Granuloma, Inflammatory mass, Intraspinal drug therapy, Intrathecal catheter, Morphine pump",
author = "Coffey, {Robert J.} and Kim Burchiel",
year = "2002",
month = "1",
doi = "10.1097/00006123-200201000-00014",
language = "English (US)",
volume = "50",
pages = "78--86",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Inflammatory mass lesions associated with intrathecal drug infusion catheters

T2 - Report and observations on 41 patients

AU - Coffey, Robert J.

AU - Burchiel, Kim

PY - 2002/1

Y1 - 2002/1

N2 - OBJECTIVE: Several reports have described inflammatory mass lesions at the tip of intraspinal drug administration catheters. We evaluated the number of patients reported with this condition and whether data support hypotheses that have been put forth regarding the cause of these lesions. METHODS: Information that was reported in the medical literature, and by Medtronic, Inc., to the United States Food and Drug Administration as of November 30, 2000, was reviewed. RESULTS: Forty-one cases were identified, including 16 from the literature and 25 that were not published previously in the literature. Because of voluntary reporting and other methodological limitations, the actual number of cases must be higher than reported. All of the patients had chronic pain. The mean duration of therapy was 24.5 months. Most masses were located in the thoracic region, Intrathecal drugs included morphine or hydromorphone, either alone or mixed with other drugs, in 39 of 41 cases. No masses were reported in patients who received baclofen as the only intrathecal medication. Thirty patients underwent surgery to relieve spinal cord or cauda equina compression. Eleven patients were nonambulatory at last follow-up, and one died of a pulmonary embolus. Surgical specimens revealed noninfectious chronic inflammation, granuloma formation, and fibrosis or necrosis. DISCUSSION: The most plausible hypothesis with regard to the cause of intrathecal catheter tip mass lesions implicates the administration of relatively high-concentration or high-dose opiate drugs or the use of drugs and admixtures that are not labeled for intrathecal use. CONCLUSION: Patients who require high-dose intraspinal opioid therapy and those who receive drugs or admixtures that are not approved for intrathecal use should be monitored closely for signs of an extra-axial mass or catheter malfunction. Prompt diagnosis and treatment may preserve neurological function.

AB - OBJECTIVE: Several reports have described inflammatory mass lesions at the tip of intraspinal drug administration catheters. We evaluated the number of patients reported with this condition and whether data support hypotheses that have been put forth regarding the cause of these lesions. METHODS: Information that was reported in the medical literature, and by Medtronic, Inc., to the United States Food and Drug Administration as of November 30, 2000, was reviewed. RESULTS: Forty-one cases were identified, including 16 from the literature and 25 that were not published previously in the literature. Because of voluntary reporting and other methodological limitations, the actual number of cases must be higher than reported. All of the patients had chronic pain. The mean duration of therapy was 24.5 months. Most masses were located in the thoracic region, Intrathecal drugs included morphine or hydromorphone, either alone or mixed with other drugs, in 39 of 41 cases. No masses were reported in patients who received baclofen as the only intrathecal medication. Thirty patients underwent surgery to relieve spinal cord or cauda equina compression. Eleven patients were nonambulatory at last follow-up, and one died of a pulmonary embolus. Surgical specimens revealed noninfectious chronic inflammation, granuloma formation, and fibrosis or necrosis. DISCUSSION: The most plausible hypothesis with regard to the cause of intrathecal catheter tip mass lesions implicates the administration of relatively high-concentration or high-dose opiate drugs or the use of drugs and admixtures that are not labeled for intrathecal use. CONCLUSION: Patients who require high-dose intraspinal opioid therapy and those who receive drugs or admixtures that are not approved for intrathecal use should be monitored closely for signs of an extra-axial mass or catheter malfunction. Prompt diagnosis and treatment may preserve neurological function.

KW - Complications

KW - Granuloma

KW - Inflammatory mass

KW - Intraspinal drug therapy

KW - Intrathecal catheter

KW - Morphine pump

UR - http://www.scopus.com/inward/record.url?scp=0036362351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036362351&partnerID=8YFLogxK

U2 - 10.1097/00006123-200201000-00014

DO - 10.1097/00006123-200201000-00014

M3 - Article

C2 - 11844237

AN - SCOPUS:0036362351

VL - 50

SP - 78

EP - 86

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 1

ER -